Neuroscience Conference

Mercure Sheffield St Paul's Hotel & Spa
Wednesday 17th July

About

Accelerating Diagnosis and Treatment of Neurological Diseases

Introducing the inaugural Bionow Neuroscience conference, created to bring together academics, clinicians and industry experts in the spirit of collaboration & growth.

The conference aims to highlight the strengths in the discovery, development and commercialisation of neuroscience treatments and technologies across North England and beyond. The event will showcase key developments across neuroscience, including a range of neurological diseases and conditions such as Alzheimer’s disease, cerebal palsy, dementia, epilepsy, Huntington’s disease, motor neurone disease (MND) and Parkinson’s disease.

Why attend?

The Bionow Neuroscience Conference will explore the current challenges and opportunities facing Neuroscience, highlighting new approaches that will create opportunities for R&D, commercialisation and implementation plus will consider the impact on patient outcomes.

Bringing the expertise, funding and new technologies together in the neuroscience field is one of the biggest challenges facing the Life Sciences sector and society at large. The aim of this conference is to bring together all these elements and contribute to the eradication of these diseases.

Key Information

Date: Wednesday 17th July 2024

Venue: Mercure Sheffield St Paul's Hotel & Spa, 119 Norfolk St, Sheffield City Centre, Sheffield S1 2JE

Registration will be open soon!

09:00 Conference Welcome
09:05 Keynote
Dame Pamela Shaw, Director of the Sheffield Institute for Translational Neuroscience, University of Sheffield
09:30 State of the Nation Panel
Chair: Kevin Cox, Non-Executive Director, British Neuroscience Association

Laura Ajram, CEO, British Neuroscience Assocation

Heather Mortiboys, Professor of Cellular Neuroscience and Metabolism, University of Sheffield

Shadi Farhangrazi, CEO & Co-founder, SM Discovery Group
10:30 Tea, Coffee & Networking
11:00 Early Diagnosis and Detection
Dale Athey, CEO, ESP Diagnostics

Oliver Bandmann, Professor of Movement Disorders Neurology, University of Sheffield
12:00 Treatments of the future and Where are we now?
Andy Whiting, CEO, Nevrargenics

Paul Chazot, Professor of Pharmacology, Durham University

Ruth Roberts, Co-founder of Apconix and Professor at University of Birmingham
13:30 Lunch
14:40 Keynote 2
15:05 Funding and Investment Panel
Sara Imarisio,Strategy Leader for Neuroscience, Medicine Discovery Catapult

Sara Rodrigues, Senior Research Manager, ARUK

Arthur Roach, Director, Parkinson's UK Virtual Biotech

Jenny Barnett, CEO, Monument Therapeutics
16:05 Tea, Coffee & Networking
16:20 Patient Perspective
16:35 Poster Board Session
16:50 Conference Close

Keynote Speakers

Dame Pamela Shaw
Director of the Sheffield Institute for Translational Neuroscience, University of Sheffield

Director of the Sheffield Institute for Translational Neuroscience

Pamela Shaw is Professor of Neurology at the University of Sheffield and Director of: the Sheffield Institute for Translational Neuroscience (SITraN); the NIHR Sheffield Biomedical Research Centre for Translational Neuroscience and the Sheffield Care and Research Centre for Motor Neuron Disorders. She is a Clinician Scientist in Neurology, formerly a Wellcome Trust Senior Fellow and an NIHR Senior Investigator.

Her work investigates genetic, molecular and neurochemical mechanisms underlying ALS/MND; identifies new therapeutic targets and translates new neuroprotective and symptomatic treatment approaches into the clinic, including genetic therapy approaches. She has active programmes in systematic biosample collection and biomarker identification in ALS/MND. From 2009-2016 she initiated and led the national UK Clinical Studies Group for ALS/MND, a clinical research and trials network which links 23 ALS/MND Care and Research Centres. Prof. Shaw has taken part in more than 25 ALS/MND clinical trials, including roles as Chief Investigator and Steering Committee member.

She has authored more than 570 publications (H-index 120). Her research is funded by NIHR, the UK Medical Research Council, Wellcome Trust, MND Association, MyName’5 Doddie Foundation, Fight MND (Australia) and Department of Defense (US), EU and biotech/ pharmaceutical industry partners.

Pamela Shaw has received multiple national and international awards for her work including: DBE for Services to Neuroscience; American Academy of Neurology Sheila Essey Award; International ALS/MND Alliance Forbes Norris Award; Royal College of Physicians Jean Hunter Award; FMedSci; Fellowship American Association for the Advancement of Science; ABN Medallist-2019; Queen’s Anniversary Award to SITraN-2019; British Neuroscience Association Outstanding Contribution Award 2022.

Registration

Member Delegate Pass

£149 + VAT

Member Gold Exhibitor Package

£485 + VAT

Member Silver Exhibitor Package

£412 + VAT

Non-Member Delegate Pass

£209 + VAT

Non-Member Gold Exhibitor Package

£550 + VAT

Non-Member Silver Exhibitor Package

£475 + VAT

Premium Member Gold Exhibitor Package

£422 + VAT

Premium Member Silver Exhibitor Package

£348 + VAT

Gold Exhibitors

Venue

Bionow's Neuroscience Conference will be held at the Mercure Sheffield St Paul's Hotel & Spa.

Venue

Mercure Sheffield St Paul's Hotel & Spa

Location

119 Norfolk St,
Sheffield City Centre,
Sheffield
S1 2JE

Travel

The hotel is located in the heart of Sheffield City Centre and is less than a 10 minute walk from Sheffield Train Station.

Parking

Q Park, Charles Street (aka. The Cheese Grater) 25% discount on advertised rates,
Sat Nav: S1 2NB Directions to the hotel: Leave the car park from the ground floor, walking in the direction of Cosmo and Piccolinos.
The hotel is within 50m straight ahead of you.

Neuroscience Conference